Molecular Medicine SpA logo

MLM - Molecular Medicine SpA Share Price

€0.517 0.0  0.0%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £219.6m
Enterprise Value £213.6m
Revenue £31.5m
Position in Universe 265th / 721
Bullish
Bearish
Unlock MLM Revenue
Momentum
Relative Strength (%)
1m -1.34%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.15%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
11.2 13.6 19.5 23.0 28.4 34.3 +25.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Molecular Medicine SpA revenues increased 25% to EUR20.4M. Net income totaled EUR2.4M vs. loss of EUR1.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and Development decrease of 91% to EUR167K (expense), Other revenue increase from EUR63K to EUR379K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MLM
Graphical History

Revenue

MLM Revenue Unlock MLM Revenue

Net Income

MLM Net Income Unlock MLM Revenue

Normalised EPS

MLM Normalised EPS Unlock MLM Revenue

PE Ratio Range

MLM PE Ratio Range Unlock MLM Revenue

Dividend Yield Range

MLM Dividend Yield Range Unlock MLM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MLM EPS Forecasts Unlock MLM Revenue
Profile Summary

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company’s activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed’s pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since March 5, 2008
No. of Shareholders: n/a
No. of Employees: 223
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Borsa Italiana
Shares in Issue 463,450,672
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MLM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MLM
Upcoming Events for MLM
Wednesday 11th November, 2020
Ionis Pharmaceuticals, UCSD Cellular and Molecular Medicine, Nature Biotechnology, and Nature Structural & Molecular Biology RNA at the Bench and Bedside II Conference (Virtual)
Frequently Asked Questions for Molecular Medicine SpA
What is the Molecular Medicine SpA share price?

As of 18/09/20, shares in Molecular Medicine SpA are trading at €0.517, giving the company a market capitalisation of £219.6m. This share price information is delayed by 15 minutes.

How has the Molecular Medicine SpA share price performed this year?

Shares in Molecular Medicine SpA are currently trading at €0.517 and the price has moved by 35.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Molecular Medicine SpA price has moved by 45.49% over the past year.

What are the analyst and broker recommendations for Molecular Medicine SpA?

Of the analysts with advisory recommendations for Molecular Medicine SpA, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Molecular Medicine SpA is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Molecular Medicine SpA next release its financial results?

Molecular Medicine SpA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Molecular Medicine SpA dividend yield?

Molecular Medicine SpA does not currently pay a dividend.

Does Molecular Medicine SpA pay a dividend?

Molecular Medicine SpA does not currently pay a dividend.

When does Molecular Medicine SpA next pay dividends?

Molecular Medicine SpA does not currently pay a dividend.

How do I buy Molecular Medicine SpA shares?

To buy shares in Molecular Medicine SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Molecular Medicine SpA?

Shares in Molecular Medicine SpA are currently trading at €0.517, giving the company a market capitalisation of £219.6m.

Where are Molecular Medicine SpA shares listed? Where are Molecular Medicine SpA shares listed?

Here are the trading details for Molecular Medicine SpA:

Country of listing: Italy
Exchange: MIL
Ticker Symbol: MLM
What kind of share is Molecular Medicine SpA?

Based on an overall assessment of its quality, value and momentum, Molecular Medicine SpA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Molecular Medicine SpA share price forecast 2020?

We were not able to load any forecast data for Molecular Medicine SpA.

How can I tell whether the Molecular Medicine SpA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecular Medicine SpA. Over the past six months, the relative strength of its shares against the market has been -17.27%. At the current price of €0.517, shares in Molecular Medicine SpA are trading at 14.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Molecular Medicine SpA PE Ratio?

The Molecular Medicine SpA PE ratio based on its reported earnings over the past 12 months is 0.848k. The shares are currently trading at €0.517.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Molecular Medicine SpA?

Molecular Medicine SpA's management team is headed by:

Claudio Bordignon - CEX
Sabina Grossi - NED
Alfredo Messina - NED
Antonio Lambiase - OTH
Cynthia Giuliani - DHR
Alberto Carletti - NED
Marco Manoni - OTH
Mario Masciocchi - IND
Riccardo Palmisano - CEO
Laura Ferro - IND
Carlo Incerti - CHM
Luca Alberici - OTH
Tiziano Andreoli - OTH
Simona Rovetta - OTH
Salvatore Calabrese - CFO
Who are the major shareholders of Molecular Medicine SpA?

Here are the top five shareholders of Molecular Medicine SpA based on the size of their shareholding:

AGC Inc Corporation
Percentage owned: 93.23% (432.1m shares)
Cigogne UCITS - M&A Arbitrage Mutual Fund
Percentage owned: 1.47% (6.83m shares)
Cigogne Management S.A. Investment Advisor/Hedge Fund
Percentage owned: 1.47% (6.83m shares)
Mediolanum Gestione Fondi SGR p.A. Investment Advisor
Percentage owned: 1.41% (6.51m shares)
Mediolanum Flessibile Sviluppo Italia L Mutual Fund
Percentage owned: 0.96% (4.46m shares)
Similar to MLM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.